Services

Drug Development Solutions: supporting informed decision-making during discovery and preclinical drug development

• CXR combines proprietary technologies with improved application of traditional preclinical techniques and assays, including in vitro and in vivo ADME and Toxicology studies; cell culture; and an extensive analytical capability.
• We work with you in a flexible, consultative and advisory manner to design and interpret programs that deliver the results you need, whilst reducing time, cost and use of animals.
• Services range from one-off problem-solving studies to comprehensive hits-to-lead programmes
• CXR also offers a range of proprietary and predictive oncology-focused services.

Investigative and Mechanistic Toxicology: by understanding the pathways that define the sensitivity of cells to chemicals, we evaluate the actual hazard to man

• We have extensive experience in evaluating toxicological processes across species, and determining the relevance to man of observed adverse reactions to the satisfaction of regulatory bodies.
• Using this approach, we have ‘rescued’ compounds that may otherwise have been abandoned by industry.
• CXR will work with you to design state of the art investigative safety studies to understand the mechanisms of adverse preclinical observations, interpret the results and, if required, make recommendations as to the future of the project.
• We can prepare the documentation required for product support and accreditation (e.g. REACH).
• CXR also develops and applies new technologies for safety evaluation.
  

We provide services and expertise on a fee-for-service basis, and our proprietary models are available to licenc